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A B S T R A C T
Purpose: Photosensitive epilepsy (PSE) is a form of reﬂex epilepsy characterized by seizures triggered by
light. Genetic factors play an important role and some studies have indicated a possible role of the
Bromodomain-Containing Protein 2 (BRD2) gene. Our aim was to investigate the relationship between
PSE and mutations of the BRD2 gene.
Methods: Fifty-four PSE patients with normal ﬁndings on neurological examination and neuro-imaging
studies were included. All had a clear photoparoxysmal response in the EEG as reported by 2 experienced
EEG interpreters. We investigated the BRD2 gene by denaturing high performance liquid chromatogra-
phy followed by direct DNA sequencing.
Results: We failed to detect any mutations of the BRD2 gene. However, several single-nucleotide
polymorphisms (SNPs) were observed in the gene; three of them were novel SNPs. The comparison of the
patients showing these SNP changes with the remaining patients suggested a link between carrier status
and prognosis.
Conclusion: Our study did not conﬁrm the presence of the genetic variants previously found to link the
BRD2 gene to the idiopathic form of photosensitive epilepsy. SNP changes of the BRD2 gene may be
clinically relevant but these ﬁndings need to be veriﬁed by larger studies.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Photosensitivity is an abnormal, exaggerated response of the
brain to light deﬁned by the occurrence of spikes or spikes and
waves in response to intermittent photic stimulation (IPS) in the
electroencephalogram (EEG).1,2 Photosensitive epilepsy (PSE) is a
heterogeneous genetic epilepsy with seizures triggered by IPS or
daily light sources.1,2 Photosensitivity is frequently observed in
idiopathic (genetic) generalized epilepsy (IGE) especially in its
subtypes juvenile myoclonic epilepsy (JME), childhood and
juvenile absence epilepsy, and also in the idiopathic photosensitive
occipital lobe epilepsy (IPOE).3,4
Although PSE is commonly observed in the neurology practice,
its pathophysiology has not yet been explained. Genetic factors
play an important role and one study has indicated a relation with
the Bromodomain-Containing Protein 2 (BRD2) gene.5 Highly§ This study was presented in a preliminary form as a poster in the 63rd Annual
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http://dx.doi.org/10.1016/j.seizure.2012.06.008signiﬁcant linkage disequilibrium (LD) was shown between JME
and a core haplotype of ﬁve single-nucleotide-polymorphism
(SNP) and microsatellite markers with LD peaking in the BRD2
(RING3) gene.6 Lorenz et al. reported allelic and haplotypic
associations between photoparoxysmal response (PPR) and six
BRD2 polymorphisms in 187 subjects exhibiting PPR and 666
healthy controls.5 Considering the strong neurobiological associa-
tion of JME with PPR, these results suggested that PPR and JME may
share epileptogenic pathways, for which the BRD2 gene variations
might be an underlying susceptibility factor.5
Our aim was to investigate the relationship between idiopathic
PSE and the mutations or polymorphisms of the BRD2 gene in a
group of Turkish patients. We also assessed whether patients with
variants of BRD2 differ from patients without these variants.
2. Materials and methods
We included 54 patients with idiopathic/genetic epilepsy
having a clear photoparoxysmal response in at least one EEG as
reported by 2 experienced interpreters. All participants had normal
ﬁndings on neurological examination and neuro-imaging studies.
The patients with epileptic discharges during resting EEG or during
hyperventilation had at least two-fold or more increase in the
epileptic discharges during IPS. All patients were followed up by
the same Epilepsy Center at least for 2 years to determine the
prognosis. They underwent interictal or ictal EEG studies. EEGvier Ltd. All rights reserved.
Table 2
Comparison of patients with and without SNP changes in the BRD2 gene.
Group1
(n: 26)
Group2
(n: 28)
P value
Poor prognosis (no remission) 8 17 0.03a
1st degree consanguineous marriage 5 5 Ns
Family history of epilepsy 16 10 Ns
JME syndrome 18 16 Ns
Recorded seizure during IPS 8 14 Ns
Absence seizures 10 13 Ns
Generalized tonic–clonic convulsions 22 22 Ns
JME, juvenile myoclonus epilepsy; IPS, intermittent photic stimulation; ns, not
signiﬁcant. Group 1, patients with single nucleotide polymorphism in the BRD2
gene. Group 2, patients without SNPs in the BRD2 gene.
a Fisher’s exact test.
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started eyes open for 5 s and then eyes closed for 5 s; the stimulus
train was given in a screening phase with 5–10–15–20–25–30–
35 Hz as described elsewhere.4 Clinical photosensitivity was
deﬁned as the self-report of the patients stating that their seizures
were induced by light during daily life (sunlight, TV, video games,
patterns, etc.).
All patients’ clinical and EEG ﬁles were evaluated in detail for
characteristics such as sex, current age, median age at onset,
triggers for seizures in daily life, seizure types and syndrome
classiﬁcation. An epilepsy syndrome diagnosis was made for each
patient, based on the clinical and EEG features according to the
International League Against Epilepsy (ILAE) classiﬁcation. The
patients with myoclonia as the predominant seizure type were
diagnosed as juvenile myoclonic epilepsy, whereas the others
having absence seizures were grouped according to the age at
onset before and after 10 years, as childhood or juvenile absence
epilepsy. The study was approved by the local ethics committee
and all patients gave written informed consent. The remission for
2 years and relapses were also evaluated.
DNA was extracted from blood samples using Qiagen DNA
extraction kit. Speciﬁc primers for each exon, including exon–
intron boundary sites were designed with the BRD2 sequence
taken from NCBI (NM_001113182.2) database by using ‘‘primer3’’
software (http://frodo.wi.mit.edu/primer3/). After optimization
stage, polymerase chain reaction (PCR) was performed for all 13
exons and PCR products were controlled with 3% agarose gel
electrophoresis. Ampliﬁed PCR products were scanned through the
dHPLC (denaturing high-performance liquid chromatography)
system (WAVE System Model 3500 HT) in speciﬁc conditions.
Denaturation patterns of all amplicons were carefully investigated
and those samples having any deﬂection over others were
conﬁrmed by bidirectional sequencing (for both 50 and 30 strands).
We used Fisher’s exact test to compare clinical ﬁndings
between the group of patients who have at least one variation
and the group of patients without variation. P values less than 0.05
were considered statistically signiﬁcant.
3. Results
There were 40 women and 14 men diagnosed with PSE and
their current ages were between 12 and 63 years. The median age
at onset of the seizures was 13.1  5.5 years. Fifty-two patients were
diagnosed with IGE (34 with JME, 4 with childhood absence epilepsy,
10 with juvenile absence epilepsy, 4 with late-onset IGE) and the
remaining two patients were diagnosed with IPOE.4 All patients had
PPR in the EEG and 43 patients also reported seizures triggered by
light in their daily life (TV in 16 pts, sunlight in 17, computer/video
7 pts, patterns 4 pts).
The variants found after sequencing analysis are presented in
Table 1. Three unknown variants were found, but none of themTable 1
Sequenced samples and variations of the BRD2 gene.
Number of
patientsa
Variant Position Aminoacid
Change
2 rs9276935; heterozygous 50 UTR –
2 rs55912052; heterozygous 50 UTR –
2 rs516535; heterozygous Exon 3 Lys > Lys
1b c.177C>A; heterozygous Exon 3 Ala > Ala
13 rs15912; hetero-homozygous Exon 6 Leu > Leu
1b c.2147-10A>C Intron –
6 rs2071876; heterozygous Exon 13 Ser > Ser
1 rs3918140; heterozygous Exon 13 Ser > Ser
2b c.3053G>A 30 UTR –
a Some patients have more than one variation.
b Unknown variants.cause any aminoacid change or splicing defect. The other variants
were well-known polymorphisms.
We compared the clinical and EEG features of the patients
showing these SNP changes (26 cases), with the remaining patients
without any SNP changes (28 patients) using the nonparametric
Fisher’s exact test. We found a statistically signiﬁcant association
of the SNPs in the BRD2 gene with the prognosis (which is deﬁned
as seizure remission for 2 years under anti-epileptic drug therapy
for 26 patients versus no remission in 28 patients, P = 0.03) as
shown in Table 2.
4. Discussion
Reﬂex seizures and epilepsies are well-known entities, which
create a human model that can help with the understanding of the
basic mechanisms underlying epilepsy. The increased risk of
exposure to potentially ictogenic artiﬁcial light sources associated
with modern life makes photosensitive epilepsy (PSE) an impor-
tant issue to study.7
The chromosomal region on 6p21 has shown linkage to
various IGE syndromes, particularly to JME and also PSE.8,9 The
BRD2 gene, a putative nuclear transcriptional regulator from a
family of genes that are expressed during development, is a good
positional candidate. Pal et al. reported two JME-associated SNP
variants in the BRD2 (RING3) promoter region and suggested
that the BRD2 gene is EJM1, the ﬁrst gene identiﬁed for JME.6
These ﬁndings also suggested that abnormalities of neural
development may cause common idiopathic epilepsy.6 Recently,
in a heterozygous BRD2+/ mice model, Velı´sˇek et al. reported
that the non-channel-encoding, developmentally critical
BRD2 gene is associated with sex-speciﬁc increases in the
seizure susceptibility, which is also a well-known feature in
human PSE.10 The seizure-related anatomical changes in the
GABA system further supported BRD2’s involvement in human
IGE.10
The BRD2 gene expresses distinct tissue-speciﬁc transcripts
that originate from different promoters and have strikingly
different lengths of 50 untranslated regions (50UTR). It was also
experimentally conﬁrmed that the presence of a highly conserved,
but alternatively spliced exon would result in a premature
termination of translation. These multiple levels of regulation
would affect the production of functional BRD2 protein during
neural development, hence its role in the etiology of seizure
susceptibility.11
The association between JME/PPR and the BRD2 gene has been
reported with different alleles in different studies. Furthermore
some population studies have shown association with the
promoter region, whereas the others with the 3-end. On the
other hand, the replication studies for both regions failed in some
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between markers in the BRD2 region and PPR in German
individuals, 59% of whom also had IGE.5 A following multi-center
study typed a single SNP (the promoter variant rs3918149) in the
promoter of JME patients from ﬁve independent European
populations consisting of 531 JME cases and 1390 healthy
controls. They observed a signiﬁcant effect in a small sample
recruited in Britain, a borderline signiﬁcant effect in a sample
recruited in Ireland and no associations in larger samples of
German, Australian, and Indian populations, interestingly.12 The
Dutch group further investigated three SNP markers in the 3-end
of the BRD2 gene showing the strongest association in the study
with German individuals. They found no signiﬁcant difference
between the allele frequencies in cases and controls for these
chosen markers.13 Due to these inconclusive results, we investi-
gated this plausible gene with a different technique in a different
ethnic cohort. Our results suggested that mutations of the BRD2
gene did not seem to be frequently associated with idiopathic
photosensitive epilepsy in Turkish epileptic patients. Due to the
lack of a healthy control group in our study, our results should be
interpreted with caution. We want to emphasize that there is
currently no diagnostic role of the BRD2 gene investigations in
clinical practice.
We also tested a hypothesis that SNP changes of the BRD2 gene
might be clinically relevant. The comparison of the patients
showing these SNP changes with the remaining patients suggested
a link between carrier status and prognosis. It was interesting to
note that a poor prognosis for PSE (no remission for 2 years under
appropriate anti-epileptic drug therapy) is more common in the
group without any SNP changes of the BRD2 gene. This peculiar
result may indicate a potential protective or therapy modulating
effect of SNP changes of the BRD2 gene but this ﬁnding needs to be
veriﬁed by larger studies.
In conclusion, our study did not conﬁrm the presence of the
genetic variants previously found to link the BRD2 gene to
the idiopathic form of photosensitive epilepsy in Turkish
patients.Acknowledgement
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